SOURCE-LINKED STUDY SUMMARY
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.
Abstract summarizedQuality not appraised
- What was studied
- A phase 2 trial tested a triple-receptor agonist for weight reduction.
- Who / model studied
- 205 adults with overweight/obesity and no diabetes.
- Studied dose & schedule
- Weekly subcutaneous UBT251 targets of 2, 4 or 6 mg versus placebo for 24 weeks; two starting schedules for the 4 mg target. Route confirmed in the registry.
- What the study found
- Weight changed -19.7% to -13.6% across active groups, versus -2.0% with placebo. Gastrointestinal events were most frequent, generally mild or moderate.
- Limitations & context
- No head-to-head retatrutide comparison. Weight change does not establish fat-specific loss or muscle preservation. Detailed discontinuation counts and alternative estimands were unavailable. New journal report, not necessarily first disclosure; abstract assessment.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.cmet.2026.09.021